SHAREHOLDER ALERT: WeissLaw LLP Reminds NGA, FIII, and SNSS Shareholders About Its Ongoing Investigations

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- 

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Northern Genesis Acquisition Corp. NGA

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Northern Genesis Acquisition Corp. NGA in connection with the company's proposed merger with The Lion Electric Co.  Under the terms of the merger agreement, NGA will acquire Lion Electric Co. through a reverse merger that will result in Lion Electric Co. becoming a publicly-traded company.  If you own NGA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:  https://www.weisslawllp.com/nga/ 

Forum Merger III Corporation FIII

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Forum Merger III Corporation FIII in connection with the company's proposed merger with Electric Last Mile, Inc. ("ELMI"). Under the terms of the merger agreement, FIII will acquire ELMI through a reverse merger that will result in ELMI becoming a publicly-traded company.  If you own FIII shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/fiii/  

Sunesis Pharmaceuticals, Inc. SNSS

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sunesis Pharmaceuticals, Inc. SNSS in connection with the company's proposed merger with Viracta Therapeutics, Inc. ("Viracta")  Under the terms of the merger agreement, SNSS and Viracta will combine, resulting in current Viracta stockholders owning 86% of the post-close company and leaving only 14% of the surviving entity to current SNSS stockholders.  If you own SNSS shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/snss/

SOURCE WeissLaw LLP